The 2012 Galapagos-GlaxoSmithKline alliance has been partly idled. Belgium-based Galapagos announced Monday that GSK has stopped Phase-II exploration of its JAK1 inhibitor GSK2586184 for systemic lupus erythematosus due to lack of effect.
Galapagos said that GSK has put an exploratory half-phase test of this same inhibitor in ulcerative colitis on hold.
Phase-II dosing in a third scenario—psoriasis—has wrapped and the company expects to provide top-line results in the first half of this year. This endpoint means GSK may cough up a milestone payment if results equal proof-of-concept.
